Computed tomographic perfusion abnormalities in acute migraine with aura: Characteristics and comparison with transient ischemic attack

EUROPEAN Stroke Journal

European Stroke Journal 2022, Vol. 7(4) 431–438 © European Stroke Organisation 2022

Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/23969873221114256 journals.sagepub.com/home/eso

Davide Strambo^{1*}, Stefania Nannoni^{1*}, Leonor Rebordão², Vincent Dunet³ and Patrik Michel¹

Abstract

Introduction: Migraine with aura (MA) accounts for up to 10% of "stroke mimics" and can present cerebral perfusion abnormalities. We aimed to compare perfusion-CT (PCT) findings in acute-onset MA mimicking an ischemic stroke with those observed in transient ischemic attack (TIA).

Methods: We retrospectively studied patients admitted to our hospital between 2002 and 2014 with suspicion of acute ischemic stroke, having PCT and receiving a final diagnosis of MA. We visually assessed PCT for the presence and extent of focal hypoperfusion (FHP). MA patients with FHP were compared with consecutive TIA patients showing FHP. We performed both qualitative and quantitative analysis of PCT.

Results: Of 47 patients with MA (median age=33 years, 55% females), 16 (34%) displayed FHP. Compared to MA patients without FHP, MA patients with FHP had similar headaches and aura features, but a less frequent history of MA (p=0.010). Compared to 74 TIA patients with FHP (median age=69 years, 43% females), MA patients with FHP showed hypoperfusion that more frequently involved adjacent vascular territories or a whole hemisphere (p<0.001). In addition, hypoperfusion in MA patients had a less pronounced increase in rMTT (1.2 vs 1.8, p<0.001) and rTTP (1.1 vs 1.2, p<0.001), and a lesser decrease in rCBF (0.8 vs 0.6, p<0.001) compared to hypoperfusion in TIA. rMTT displayed the best discriminative ability to differentiate MA from TIA.

Conclusion: Focal perfusion abnormalities in acute MA often involve adjacent vascular territories and hypoperfusion is less pronounced than in TIA. MA can be best differentiated from TIA by a smaller rMTT increase.

Keywords

Migraine aura, CT perfusion, transient ischemic attack

Date received: 27 June 2022; accepted: 29 June 2022

Introduction

Between 14% and 45% of patients with suspected acute ischemic stroke are affected by a non-stroke condition having a similar clinical presentation (stroke-mimics).^{1,2} After seizures and psychiatric disorders, migraine with aura (MA) is the third most common cause of such a condition, accounting for up to 10% of stroke mimics.^{1,2} Indeed, MA is responsible for about 18% of all erroneous thrombolytic treatments.²

MA is defined as visual, auditory, somatosensory, or motor symptoms associated with migraine attacks, characterized by their gradual evolution (usually over 5–20 min) and a maximum duration of 60 min for each individual symptom.³ The cortical spreading depression characteristic of MA is usually accompanied by a short-lasting cerebral hyperperfusion of about $1-2 \min$ and a subsequent mild hypoperfusion of about 1-2 h.⁴

¹Stroke Center, Neurology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

²Department of Neurology, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal

³Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland

*Contributed equally.

Corresponding author:

Davide Strambo, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital, Rue du Bugnon 46, Lausanne 1011, Switzerland. Email: strambodavide@gmail.com In the emergency room (ER), differential diagnosis between MA and acute ischemic stroke (AIS) or transient ischemic attack (TIA) can be challenging. Improving the diagnostic accuracy is important, in order to avoid inappropriate therapies such as IV thrombolysis or unnecessary work-up and tertiary prevention for cerebrovascular diseases.

In the acute assessment of AIS and TIA patients, perfusion-CT (PCT) imaging is adopted widely and becoming a validated tool for identification of patients with good potential for acute recanalization therapies.^{5,6} However, the role of PCT in the acute evaluation of patients with MA has only been explored in single patient reports or small case series.^{7,8}

The aim of our study is to assess the frequency of focal hypoperfusion (FHP) on PCT and the variables associated in a consecutive series of patients presenting with a clinical suspicion of AIS or TIA who underwent PCT and who received a final diagnosis of MA. In addition, we aimed to compare the characteristics of FHP in MA patients and in a control group of TIA patients with FHP.

Methods

Patient selection

We did a retrospective study including all patients admitted to the ER of our university hospital between 2002 and 2014 with clinical suspicion of AIS or TIA, who underwent acute PCT and who received a final diagnosis of event compatible with migraine attack with aura (MA). Included patients either fulfilled the International Classification of Headache Disorders (ICHD) criteria for migraine with aura,³ or missed the criterion A only, that is presented with a first episode fulfilling all other criteria of migraine with aura, which was considered the most likely pathophysiological process according to a board-certified neurologist. In all cases the final diagnosis of MA was based on repeat history taking by board certified neurologists and follow-up MRI performed after the initial presentation, beyond the initial 24 h after symptom onset.

The inclusion criteria of the present study were: MA with hemispheric/lateralized symptoms and without symptoms suggestive of a migraine with brainstem aura (such as severe vertigo or diplopia); and the availability of a good quality PCT performed within 24 h of symptoms onset.

For each included patient we collected: demographics, vascular risk factors, personal history of headache, family history of migraine, neurological symptoms/signs, duration of neurological deficits and characteristics of migraine. We distinguished the modality of symptoms onset into (1) acute; (2) progressive topographical spreading of the initial symptoms, for example sensory deficit extending from the face to the arm; (3) sequential: sequence of different symptoms appearing one after the other (e.g. initial visual symptoms followed by the onset of aphasia). We recorded if symptoms were present during neuroimaging and, if not, the time between the end of the symptoms and PCT.

As control group, we identified all consecutive patients admitted to the ER of our hospital for hemispheric TIA in the same study period who underwent PCT within 24 h of symptoms onset, and who showed focal hypoperfusion (FHP) on PCT.

No informed consent nor local ethical committee approval was required for retrospective analysis of anonymized data according to the legislation of the Canton de Vaud, Switzerland.

Neuroimaging protocol and processing

In our institution, cerebral PCT following non-contrast CT (NCCT) and CT angiography of the head and neck is performed as part of the emergency diagnostic workup for patients with a clinical suspicion of AIS or TIA. We carried out cerebral CT on a 16-multidetector CT scanner (LightSpeed, GE Healthcare, Milwaukee, WI, USA) until November 2005 and on a 64-multidetector CT scanner (LightSpeed VCT, GE Healthcare, Milwaukee, WI, USA) thereafter. We acquired all PCT series in axial scan mode with 80 kV peak tube voltage, 240 mA tube current, 32 cm SFOV and 512×512 matrix. PCT series were positioned at the level of the basal ganglia and the third ventricle, above the orbits in order to protect the lens. We used 18 groups of 4 slices of 10 mm (40 mm z-axis coverage) until November 2005, and 18 groups of 16 slices of 5 mm (80 mm z-axis coverage) thereafter.

PCT raw data were reconstructed using FBP until February 2009 and using a blend of 40% ASiR with 60% FBP thereafter. We then analyzed PCT data using the Brilliance Workspace Portal[®] (Philips Medical Systems, Cleveland, OH, USA), based on the central volume principle. We used deconvolution to create parametric maps of time to peak (TTP), mean transit time (MTT); we calculated cerebral blood volume (CBV) maps from the area under the time-enhancement curves and cerebral blood flow (CBF) was derived from the formula CBF=CBV/MTT.

We defined FHP as any area that presented MTT increase or CBF decrease compared to contralateral mirror area on visual assessments, visible on ≥ 2 consecutive slices and not attributable to an underlying chronic tissue lesion (as shown in the two exemplary cases in Figure 1). A vascular neurologist and a neuroradiologist blinded to the clinical symptoms independently analyzed PCT for qualitative analysis, scoring FHP as absent, focal, single vascular territory, adjacent territories or hemispheric. On a subsample of 40 patients, we calculated inter-rater agreement, which was substantial according to the Prevalence and Bias Adjusted Kappa of 0.69, similar to previous studies.⁹ For patients showing FHP, we measured the ratio of PCT parameters (TTP, MTT, CBV, and CBF) between the visibly hypoperfused region and the contralateral side. A neuroradiologist with 12 years of experience and blinded to the clinical diagnosis manually delineated apparent FHP areas on all consecutive slices. The region-of-interest was automatically copied and pasted onto



Figure I. Two exemplary cases of perfusion CT analysis in a patient with migraine (upper panels) and in a patient with a TIA (lower panels). Raw images, time to peak, mean transit time, cerebral blood volume, and cerebral blood flow maps are displayed.

all parameter maps, then mirrored relative to the sagittal plane to calculate the ratio. Two exemplary cases of migraine and TIA, respectively are displayed in Figure 1.

Statistical analysis

Continuous data are presented as median value and interquartile range (IQR), categorical data as absolute numbers and percentages and quantitative data from PCT as means and standard deviation.

First, we compared MA patients with and without FHP on acute PCT, using descriptive statistics and univariate analysis. Second, we compared the subgroup of MA patients with FHP with the control group of patients with hemispheric TIA and FHP. Group comparisons were performed with Fisher's exact test (for categorical variables) and Kruskal-Wallis test (for numerical variables), considering significant *p*-values of <0.05. For PCT parameters showing significant differences between MA and TIA patients with FHP, we performed ROC curve analyses with computation of respective AUCs (95% CI). We used Liu method to identify the PCT values with highest sensitivity and specificity to correctly diagnose MA.

We performed statistical analysis with R statistical software (version 3.3.2, R Core Team [2016], R Foundation for Statistical Computing, Vienna, Austria).

This observational study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and with the Standards for Reporting Diagnostic accuracy studies (STARD) guidelines.

Data availability statement

Anonymized participant data are available upon reasonable request that includes a data analysis, authorship, and publication plan.

Results

Characteristics of MA patients with and without FHP

During the study period, we included 47 patients with MA having a median age of 33 years and 55% of whom were females. Sixteen (34%) patients displayed FHP on PCT. Compared to MA patients without FHP, MA patients with FHP had similar clinical features of headache and aura, similar onset modality (acute, progressive, or sequential), but less frequently presented a past history of MA (1/16[6.2%] vs 14/31[45.2%], p=0.010), with a similar frequency of previous episodes of migraine without aura, tension type headache or aura without headache (Table 1). Interestingly, not all patients where hypoperfusion involved the posterior cerebral artery (PCA) territory had visual symptoms during the aura, which could indicate asymptomatic aura phenomena (Among 14 patients with hypoperfusion involving the PCA territory, 5 [35%] had no visual symptoms).

Comparison of MA and TIA patients with FHP

As a control group, we analyzed 74 TIA patients with FHP (median age=69 years, 43% females). Compared with TIA patients, MA patients with FHP were younger and had a lower level of vascular risk factors (Table 2). MA patients presented a shorter duration of neurological deficits (mean 120 vs 205 min, p=0.049), had more often a clinical presentation involving sensibility alteration (69% vs 34%, p=0.021) or visual symptoms (56% vs 16%, p=0.020). Neglect was rare in both conditions.

PCT was performed at a similar time point in MA and TIA patients. Focal hypoperfusion in MA patients more frequently involved adjacent arterial territories (38% vs 3%)

| Age (years)36 (30–52.8)38 (31.3–51.8)33 (21.7–58.5)0.252Female sex26 (55.3%)18 (58.1%)8 (50%)0.252Duration of neurological deficit (minutes)190 (60–470)180 (60–300)205 (120–695)0.295Previous history of headache0.01021.5%4 (25.%)10 (32.3%)7 (43.8%)Migraine without aura11 (23.4%)7 (22.6%)4 (25.%)1Migraine without aura15 (31.9%)14 (45.2%)1 (62.3%)Tension type headache3 (6.4%)0 (0%)1 (62.3%)Aura without headache1 (21.1%)0 (0%)1 (62.3%)Family history of migraine10 (22.7%)4 (14.3%)6 (37.5%)1.000Dysarthria5 (10.6%)4 (12.9%)1 (66.8%)1.000Dysarthria5 (10.6%)4 (12.9%)1 (66.8%)1.000Limb ataxia10 (21.3%)7 (22.6%)3 (18.8%)1.000Usual symptoms27 (57.5%)18 (58.1%)9 (56.2%)1.000Negative12 (14.4%)7 (38.9%)5 (31.2%)0.0%Negative12 (14.4%)7 (38.9%)5 (55.6%)Positive and negative8 (29.6%)5 (27.8%)3 (18.8%)1.000Negative12 (25.5%)9 (29%)3 (18.8%)1.026Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)0.146Other0 (11.1%)3 (16.7%)1 (11.1%)1.62.7%)1.62.7%Negative12 (25.5%)9 (29%)3 (18.8%)1.026 <th>Variables</th> <th>Total MA patients ($n = 47$)</th> <th>No FHP $(n=31)$</th> <th>FHP (n = 16)</th> <th>þ-Value</th> | Variables | Total MA patients ($n = 47$) | No FHP $(n=31)$ | FHP (n = 16) | þ-Value |
|--|--|--------------------------------|-----------------|-------------------|---------|
| Female sex 26 (55.3%) 18 (58.1%) 8 (50.%) 0.228 Duration of neurological deficit (minutes) 190 (60–470) 180 (60–300) 205 (120–695) 0.235 Previous history of headache 17 (36.2%) 10 (32.3%) 7 (43.8%) Migraine without aura 11 (23.4%) 7 (42.6%) 4 (25%) 1 (6.2%) Migraine with aura 15 (31.9%) 14 (45.2%) 1 (6.2%) Tension type headache 3 (6.4%) 0 (0%) 3 (18.8%) L Aura without headache 1 (2.1%) 0 (0%) 1 (6.2%) Tension type headache 10 (22.7%) 4 (14.3%) 6 (37.5%) 1.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.640 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (60.7%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.068 Positive and negative | Age (years) | 36 (30–52.8) | 38 (31.3–51.8) | 33 (21.7–58.5) | 0.252 |
| Duration of neurological deficit (minutes) 190 (60–470) 180 (60–300) 205 (120–695) 0.295 Previous history of headache 07 (36.2%) 10 (32.3%) 7 (43.8%) Migraine without aura 11 (23.4%) 7 (22.6%) 4 (25%) Migraine without aura 15 (31.9%) 14 (45.2%) 1 (6.2%) Tansion type headache 1 (2.1%) 0 (0%) 3 (18.8%) Aura without headache 1 (2.1%) 0 (0%) 3 (18.8%) Aura without headache 1 (2.1%) 0 (0%) 1 (6.2%) Family history of migraine 10 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 22 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Nisual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Neglect 1 (2.1%) 1 (3.2%) 0 (0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0 (20.5%) 5 (55.6%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 0 10 (21.3%) 10 (32.3%) 8 (50%) Progressive 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 20 (42.5%) 10 (32.3%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 3 (18.8%) No headache 4 (8.5%) 1 (3.2%) 0 (0%) Cuter 0 2 (43.5%) 10 (32.3%) 4 (25%) Left predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Cuter 0 2 (4.3%) 2 (6.5%) 0 (0%) Cuter 0 2 (4.3%) 2 (6.5%) 0 (0%) Dister adality of neurological symptoms 0.256 No headache 4 (8.5%) 1 (3.2%) 0 (0%) Cuter 0 2 (4.3%) 2 (6.5%) 0 (0%) Cuter 0 2 (4.3%) 2 (3.3%) 4 (25%) Left predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 16 (34%) 12 (38.7%) 4 (25%) Left Predominant 16 (34%) 12 (38.7%) 4 (25%) Left Predominant 16 (34%) 2 (35%) 2 (12.5%) Undetermined 7 (4.2%) 2 (6.5%) 0 (0%) Difference 0 (2 (4.3%) 2 (6.5%) 0 (0%) Cuter 0 (2 (4.3%) 2 (6.5%) 0 (0%) | Female sex | 26 (55.3%) | 18 (58.1%) | 8 (50%) | 0.828 |
| Previous history of headache 0.010 None 17 (36.2%) 10 (32.3%) 7 (43.8%) Migraine with aura 11 (23.4%) 7 (22.6%) 4 (25%) Migraine with aura 15 (31.9%) 14 (45.2%) 1 (6.2%) Aura without headache 10 (22.7%) 0 (0%) 1 (6.2%) Family history of migraine 10 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms during aura - - - - Paresis 18 (38.3%) 2 (38.7%) 6 (37.5%) 0.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Uimb atxia 10 (21.3%) 7 (52.6%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 1.000 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) 0.096 1.466 Negative 12 (44.4%) 3 (16.7%) 1 (11.1%) 0.560 0.560 Positive and negative 8 (29.6%) | Duration of neurological deficit (minutes) | 190 (60-470) | 180 (60–300) | 205 (120–695) | 0.295 |
| None 17 (36.2%) 10 (32.3%) 7 (43.8%) Migraine with our aura 11 (23.4%) 7 (22.6%) 4 (25%) Tension type headache 3 (6.4%) 0 (0%) 3 (18.3%) Aura without headache 1 (2.1%) 0 (0%) 1 (6.2%) Family history of migraine 10 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms during aura 7 (22.6%) 4 (12.9%) 1 (6.2%) 1 (6.2%) 0.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.000 0.000 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (62.2%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.006 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) 0 (0%) 0.685 Positive and negative 12 (24.5%) 1 (61.7%) 1 (11.1%) 5 (65.0%) 0 (0%) 0.685 Acute 20 (42.5%) </td <td>Previous history of headache</td> <td></td> <td></td> <td></td> <td>0.010</td> | Previous history of headache | | | | 0.010 |
| Migraine without aura11(23.4%)7 (22.6%) 4 (25%) Migraine with aura15(31.9%)14(45.2%)1(6.2%)Tension type headache3(6.4%)00(0%)3(18.8%)Aura without headache1(2.1%)00(0%)1(6.2%)Family history of migraine10(22.7%)4(14.3%)6(37.5%)0.163Neurological symptoms during auraT2(38.7%)1(6.8%)0.000Dysarthria5(10.6%)4(12.9%)1(6.8%)0.000Sensory symptoms32(68.1%)21(67.7%)11(68.8%)1.000Limb ataxia10(21.3%)7(22.6%)3(18.8%)1.000Visual symptoms27(57.5%)18(58.1%)9(56.2%)1.000Neglect1(2.1%)1(3.2%)0(0%)1.000Other cognitive deficit8(17%)3(9.7%)5(55.6%)Positive and negative12(44.4%)7(38.9%)5(55.6%)Positive and negative3(11.1%)3(16.7%)1(11.1%)Positive and negative12(25.5%)9(29.%)3(18.8%)Positive and negative12(25.5%)9(29.%)3(18.8%)Progressive12(25.5%)9(29.%)3(18.8%)For | None | 17 (36.2%) | 10 (32.3%) | 7 (43.8%) | |
| Migraine with aura 15 (31.9%) 14 (45.2%) 1 (6.2%) Tension type headache 3 (6.4%) 0 (0%) 3 (18.8%) Aura without headache 1 (2.1%) 0 (0%) 1 (6.2%) Family history of migraine 10 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms during aura 9 9 1 (6.2%) 0.840 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Negative 1 (2.1%) 1 (3.2%) 0 (0%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Neglect 1 (2.1%) 1 (3.2%) 0.096 0.660 Type of visual symptoms 0.26 (55.6%) 0 (0%) 1.000 0.560 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) 0.685 6.65% 0.685 6.65% <td< td=""><td>Migraine without aura</td><td>11 (23.4%)</td><td>7 (22.6%)</td><td>4 (25%)</td><td></td></td<> | Migraine without aura | 11 (23.4%) | 7 (22.6%) | 4 (25%) | |
| Tension type headache 3 (6.4%) 0 (0%) 3 (18.8%) Aura without headache I (2.1%) 0 (0%) 1 (6.2%) Family history of migraine I0 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms during aura Paresis I8 (38.3%) 12 (38.7%) 6 (37.5%) 1.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 32 (66.1%) 21 (67.7%) II (68.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Visual symptoms 27 (57.5%) I8 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) I (3.2%) 0 (0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0 (41.4%) 7 (38.9%) 5 (55.6%) 0 Positive 12 (44.4%) 7 (38.9%) 5 (55.6%) 0 0 Positive and negative 8 (20.6%) 5 (27.8%) 3 (33.3%) 0 0 <td< td=""><td>Migraine with aura</td><td>15 (31.9%)</td><td>14 (45.2%)</td><td>l (6.2%)</td><td></td></td<> | Migraine with aura | 15 (31.9%) | 14 (45.2%) | l (6.2%) | |
| Aura without headache I (2.1%) 0 (0%) I (6.2%) Family history of migraine 10 (2.7%) 4 (14.3%) 6 (37.5%) 0.163 Paresis 18 (38.3%) 12 (38.7%) 6 (37.5%) 1.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 0.006 Aphasia 29 (1.7%) 16 (51.6%) 3 (81.2%) 0.006 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (55.6%) 0.006 Negative 12 (44.4%) 3 (16.7%) 1 (11.1%) 0.560 0.560 | Tension type headache | 3 (6.4%) | 0 (0%) | 3 (18.8%) | |
| Family history of migraine I0 (22.7%) 4 (14.3%) 6 (37.5%) 0.163 Neurological symptoms during aura | Aura without headache | I (2.1%) | 0 (0%) | l (6.2%) | |
| Neurological symptoms during aura Paresis 18 (38.3%) 12 (38.7%) 6 (37.5%) 1.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 32 (66.1%) 21 (67.7%) 11 (68.8%) 1.000 Limb ataxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Neglect 1 (2.1%) 1 (3.2%) 0.0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0 (55.6%) 0.0560 0.685 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 1 (11.1%) Positive and negative 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32. | Family history of migraine | 10 (22.7%) | 4 (14.3%) | 6 (37.5%) | 0.163 |
| Paresis 18 (38.3%) 12 (38.7%) 6 (37.5%) 1.000 Dysarthria 5 (10.6%) 4 (12.9%) 1 (6.2%) 0.840 Sensory symptoms 32 (68.1%) 21 (67.7%) 11 (68.8%) 1.000 Limb atxia 10 (21.3%) 7 (22.6%) 3 (18.8%) 1.000 Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Neglect 1 (2.1%) 1 (3.2%) 0 (0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0 (57%) 5 (55.6%) 9 9 Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) 0 Other 3 (11.1%) 3 (16.7%) 0 (0%) 0 6685 Acute 20 (42.5%) 1 (32.8%) 8 (50%) 1 7 18.8%) 1 3 1 1 1 1 1 1 1 1 3 1 3 1 1 1 1 | Neurological symptoms during aura | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Paresis | 18 (38.3%) | 12 (38.7%) | 6 (37.5%) | 1.000 |
| Sensory symptoms $32 (68.1\%)$ $21 (67.7\%)$ $11 (68.8\%)$ 1.000 Limb ataxia10 (21.3\%)7 (22.6\%) $3 (18.8\%)$ 1.000 Visual symptoms27 (57.5\%) $18 (58.1\%)$ $9 (56.2\%)$ 1.000 Aphasia29 (61.7\%) $16 (51.6\%)$ $13 (81.2\%)$ 0.096 Neglect1 (2.1\%) $1 (3.2\%)$ $0 (0\%)$ 1.000 Other cognitive deficit $8 (17\%)$ $3 (9.7\%)$ $5 (31.2\%)$ 0.146 Type of visual symptoms0.560 0.0% 0.560 Negative $12 (44.4\%)$ $7 (38.9\%)$ $5 (55.6\%)$ Positive and negative $8 (29.6\%)$ $5 (27.8\%)$ $3 (33.3\%)$ Other $3 (11.1\%)$ $3 (16.7\%)$ $1 (11.1\%)$ Positive and negative $8 (29.6\%)$ $5 (27.8\%)$ $3 (33.3\%)$ Other $3 (11.1\%)$ $3 (16.7\%)$ $0 (0\%)$ Onset modality of neurological symptoms 0.685 Acute $20 (42.5\%)$ $12 (38.7\%)$ $8 (50\%)$ Progressive $12 (25.5\%)$ $9 (29\%)$ $3 (18.8\%)$ Sequential $15 (31.9\%)$ $10 (32.3\%)$ $5 (31.2\%)$ Headache fatures 0.236 $0 (32.3\%)$ $4 (25\%)$ No headache $4 (8.5\%)$ $1 (3.2\%)$ $3 (18.8\%)$ Bilateral $16 (34\%)$ $12 (38.7\%)$ $4 (25\%)$ Unknown $1 (2.1\%)$ $1 (3.2\%)$ $0 (0\%)$ Other $2 (4.3\%)$ $2 (6.5\%)$ $0 (0\%)$ Side of aura symptoms 0.619 0.619 Right $14 (29.8\%)$ 10 | Dysarthria | 5 (10.6%) | 4 (12.9%) | I (6.2%) | 0.840 |
| Limb ataxia10 (21.3%)7 (22.6%)3 (18.8%)1.000Visual symptoms27 (57.5%)18 (58.1%)9 (56.2%)1.000Aphasia29 (61.7%)16 (51.6%)13 (81.2%)0.096Neglect1 (2.1%)1 (3.2%)0 (0%)1.000Other cognitive deficit8 (17%)3 (9.7%)5 (31.2%)0.146Type of visual symptoms0.5600.980.5600.98Negative12 (44.4%)7 (38.9%)5 (55.6%)0.560Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)0.0685Acute20 (42.5%)12 (38.7%)8 (50%)0.685Acute20 (42.5%)12 (38.7%)8 (50%)0.685Acute15 (31.9%)10 (32.3%)5 (31.2%)0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)0.236No headache16 (34%)12 (38.7%)4 (25%)0.619Left predominant6 (12.8%)10 (32.3%)8 (50%)16.2%)Left predominant16 (34%)12 (38.7%)4 (25%)0.619Side of aura symptoms0.6190.6190.619Right14 (29.8%)10 (32.3%)4 (25%)0.619Left27 (57.5%)17 (54.8%)10 (62.5%)0.619Side of aura symptoms0.6190.6190.619Time from sumptoms conset to PCT (minutes)28 (46.3%)2 (6.5%)2 (0.25%)Undetermined< | Sensory symptoms | 32 (68.1%) | 21 (67.7%) | 11 (68.8%) | 1.000 |
| Visual symptoms 27 (57.5%) 18 (58.1%) 9 (56.2%) 1.000 Aphasia 29 (61.7%) 16 (51.6%) 13 (81.2%) 0.096 Neglect 1 (2.1%) 1 (3.2%) 0 (0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0.560 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 1 (11.1%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 0 (0%) Onset modality of neurological symptoms 0.685 Acute 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) | Limb ataxia | 10 (21.3%) | 7 (22.6%) | 3 (18.8%) | 1.000 |
| Aphasia29 (61.7%)16 (51.6%)13 (81.2%)0.096Neglect1 (2.1%)1 (3.2%)0 (0%)1.000Other cognitive deficit8 (17%)3 (9.7%)5 (31.2%)0.146Type of visual symptoms0.5600.5600.560Negative12 (44.4%)7 (38.9%)5 (55.6%)Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)Other3 (11.1%)3 (16.7%)1 (11.1%)Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)Other3 (11.1%)3 (16.7%)0 (0%)Onset modality of neurological symptoms0.685Acute20 (42.5%)9 (29%)3 (18.8%)Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant18 (38.3%)10 (32.3%)8 (50%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)2 (0.0%)Time form expresences on expression expression expression expression express | Visual symptoms | 27 (57.5%) | 18 (58.1%) | 9 (56.2%) | 1.000 |
| Neglect 1 (2.1%) 1 (3.2%) 0 (0%) 1.000 Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0.560 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 1 (11.1%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 0 (0%) Onset modality of neurological symptoms 0.685 Acute 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Side of aura s | Aphasia | 29 (61.7%) | 16 (51.6%) | 13 (81.2%) | 0.096 |
| Other cognitive deficit 8 (17%) 3 (9.7%) 5 (31.2%) 0.146 Type of visual symptoms 0.560 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) Positive and negative 8 (29.6%) 3 (16.7%) 1 (11.1%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 0 (0%) Onset modality of neurological symptoms 0.685 Acute 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 0.619 Right 14 (29.8%) 10 (32.3%) | Neglect | 1 (2.1%) | I (3.2%) | 0 (0%) | 1.000 |
| Type of visual symptoms 0.560 Negative 12 (44.4%) 7 (38.9%) 5 (55.6%) Positive and negative 4 (14.8%) 3 (16.7%) 1 (11.1%) Positive and negative 8 (29.6%) 5 (27.8%) 3 (33.3%) Other 3 (11.1%) 3 (16.7%) 0 (0%) Onset modality of neurological symptoms 0.685 Acute 20 (42.5%) 9 (29%) 3 (18.8%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 0.619 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) 0.619 Left 27 (57.5%) 17 (| Other cognitive deficit | 8 (17%) | 3 (9.7%) | 5 (31.2%) | 0.146 |
| Negative12 (44.4%)7 (38.9%)5 (55.6%)Positive4 (14.8%)3 (16.7%)1 (11.1%)Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)Other3 (11.1%)3 (16.7%)0 (0%)Onset modality of neurological symptoms0.685Acute20 (42.5%)12 (38.7%)8 (50%)Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant6 (12.8%)10 (32.3%)8 (50%)Bilateral16 (34%)12 (38.7%)4 (25%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Junctermined2 (4.3%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)2 (0%)Time from symptoms onset to PCT (minutes)288.8%300 (20-413.2)230 (448.5-341.5)Image from symptoms onset to PCT (minutes)288.8%300 (20-413.2)230 (448.5-341.5)Image from symptoms onset to PCT (minutes)288.8%300 (20-413.2)230 (448.5-341.5)Image from symptoms onset to PCT (minutes)288.8%300 (20-413.2)230 (448.5-341.5) | Type of visual symptoms | × , | | () | 0.560 |
| Positive4 (14.8%)3 (16.7%)1 (11.1%)Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)Other3 (11.1%)3 (16.7%)0 (0%)Onset modality of neurological symptoms0.685Acute20 (42.5%)12 (38.7%)8 (50%)Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant6 (12.8%)5 (16.1%)1 (6.2%)Left predominant16 (34%)12 (38.7%)4 (25%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)0 (0%)Time from symptoms onset to PCT (minutes)288 (196.3–328.8)300 (220-413.2)230 (148.5–341.5) | Negative | 12 (44.4%) | 7 (38.9%) | 5 (55.6%) | |
| Positive and negative8 (29.6%)5 (27.8%)3 (33.3%)Other3 (11.1%)3 (16.7%)0 (0%)Onset modality of neurological symptoms0.685Acute20 (42.5%)12 (38.7%)8 (50%)Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant6 (12.8%)5 (16.1%)1 (6.2%)Left predominant18 (38.3%)10 (32.3%)8 (50%)Bilateral16 (34%)12 (38.7%)4 (25%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)0 (0%)Time from symptoms onset to PCT (minutes)288 (196.3-389.8)300 (220-413.2)230 (148.5-341.5) | Positive | 4 (14.8%) | 3 (16.7%) | 1 (11.1%) | |
| Other $3 (11.1\%)$ $3 (16.7\%)$ $0 (0\%)$ Onset modality of neurological symptoms0.685Acute $20 (42.5\%)$ $12 (38.7\%)$ $8 (50\%)$ Progressive $12 (25.5\%)$ $9 (29\%)$ $3 (18.8\%)$ Sequential $15 (31.9\%)$ $10 (32.3\%)$ $5 (31.2\%)$ Headache features0.236No headache $4 (8.5\%)$ $1 (3.2\%)$ $3 (18.8\%)$ Right predominant $6 (12.8\%)$ $5 (16.1\%)$ $1 (6.2\%)$ Left predominant $18 (38.3\%)$ $10 (32.3\%)$ $8 (50\%)$ Bilateral $16 (34\%)$ $12 (38.7\%)$ $4 (25\%)$ Unknown $1 (2.1\%)$ $1 (3.2\%)$ $0 (0\%)$ Other $2 (4.3\%)$ $2 (6.5\%)$ $0 (0\%)$ Side of aura symptoms0.619Right $14 (29.8\%)$ $10 (32.3\%)$ $4 (25\%)$ Left $27 (57.5\%)$ $17 (54.8\%)$ $10 (62.5\%)$ Bilateral $4 (8.5\%)$ $2 (6.5\%)$ $0 (0\%)$ Time from symptoms onset to PCT (minutres) $288 (196 (3-389.8))$ $30 (230-413.2)$ $20 (148.5-341.5)$ Dire from symptoms onset to PCT (minutres) $288 (196 (3-389.8))$ $30 (230-413.2)$ $20 (148.5-341.5)$ | Positive and negative | 8 (29.6%) | 5 (27.8%) | 3 (33.3%) | |
| Onset modality of neurological symptoms 0.685 Acute 20 (42.5%) 12 (38.7%) 8 (50%) Progressive 12 (25.5%) 9 (29%) 3 (18.8%) Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 8 (50%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Other | 3 (11.1%) | 3 (16.7%) | 0 (0%) | |
| Acute20 (42.5%)12 (38.7%)8 (50%)Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features 0.236 No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant6 (12.8%)5 (16.1%)1 (6.2%)Left predominant18 (38.3%)10 (32.3%)8 (50%)Bilateral16 (34%)12 (38.7%)4 (25%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)2 (12.5%)Time from symptoms onset to PCT (minutes)288 (196 3-389.8)300 (20.413.2)230 (148 5-341.5)Dired from symptoms onset to PCT (minutes)288 (196 3-389.8)300 (20.413.2)2341.5)0.094 | Onset modality of neurological symptoms | | (| () | 0.685 |
| Progressive12 (25.5%)9 (29%)3 (18.8%)Sequential15 (31.9%)10 (32.3%)5 (31.2%)Headache features0.236No headache4 (8.5%)1 (3.2%)3 (18.8%)Right predominant6 (12.8%)5 (16.1%)1 (6.2%)Left predominant18 (38.3%)10 (32.3%)8 (50%)Bilateral16 (34%)12 (38.7%)4 (25%)Unknown1 (2.1%)1 (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)0 (0%)Undetermined2 (4.3%)2 (6.5%)0 (0%)Time from symptoms onset to PCT (minutes)288 (196 3–389.8)300 (220-413.2)230 (148 5–341.5) | Acute | 20 (42.5%) | 12 (38.7%) | 8 (50%) | |
| Sequential 15 (31.9%) 10 (32.3%) 5 (31.2%) Headache features 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 8 (50%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Progressive | 12 (25.5%) | 9 (29%) | 3 (18.8%) | |
| Headache features 0.236 No headache 4 (8.5%) 1 (3.2%) 3 (18.8%) Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 8 (50%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Sequential | 15 (31.9%) | 10 (32.3%) | 5 (31.2%) | |
| No headache4 (8.5%)I (3.2%)3 (18.8%)Right predominant6 (12.8%)5 (16.1%)I (6.2%)Left predominant18 (38.3%)10 (32.3%)8 (50%)Bilateral16 (34%)12 (38.7%)4 (25%)UnknownI (2.1%)I (3.2%)0 (0%)Other2 (4.3%)2 (6.5%)0 (0%)Side of aura symptoms0.619Right14 (29.8%)10 (32.3%)4 (25%)Left27 (57.5%)17 (54.8%)10 (62.5%)Bilateral4 (8.5%)2 (6.5%)2 (12.5%)Undetermined2 (4.3%)2 (6.5%)0 (0%) | Headache features | | | (| 0.236 |
| Right predominant 6 (12.8%) 5 (16.1%) 1 (6.2%) Left predominant 18 (38.3%) 10 (32.3%) 8 (50%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | No headache | 4 (8.5%) | I (3.2%) | 3 (18.8%) | |
| Left predominant 18 (38.3%) 10 (32.3%) 8 (50%) Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Right predominant | 6 (12.8%) | 5 (16.1%) | 1 (6.2%) | |
| Bilateral 16 (34%) 12 (38.7%) 4 (25%) Unknown 1 (2.1%) 1 (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Left predominant | 18 (38.3%) | 10 (32.3%) | 8 (50%) | |
| Unknown I (2.1%) I (3.2%) 0 (0%) Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Bilateral | 16 (34%) | 12 (38.7%) | 4 (25%) | |
| Other 2 (4.3%) 2 (6.5%) 0 (0%) Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Unknown | 1 (2.1%) | I (3.2%) | 0 (0%) | |
| Side of aura symptoms 0.619 Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) | Other | 2 (4.3%) | 2 (6.5%) | 0 (0%) | |
| Right 14 (29.8%) 10 (32.3%) 4 (25%) Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) Time from symptoms opset to PCT (minutes) 288 (196 3–389.8) 300 (220–413.2) 230 (148 5–341.5) 0.094 | Side of aura symptoms | | | × / | 0.619 |
| Left 27 (57.5%) 17 (54.8%) 10 (62.5%) Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) Time from symptoms opset to PCT (minutes) 288 (196 3–389 8) 300 (220–413 2) 230 (148 5–341 5) 0.094 | Right | 14 (29.8%) | 10 (32.3%) | 4 (25%) | |
| Bilateral 4 (8.5%) 2 (6.5%) 2 (12.5%) Undetermined 2 (4.3%) 2 (6.5%) 0 (0%) Time from symptoms opset to PCT (minutes) 288 (196 3–389.8) 300 (220–413.2) 230 (148 5–341.5) 0.094 | Left | 27 (57.5%) | 17 (54.8%) | 10 (62.5%) | |
| Undetermined $2(4.3\%)$ $2(6.5\%)$ $0(0\%)$ | Bilateral | 4 (8.5%) | 2 (6.5%) | 2 (12.5%) | |
| Time from symptoms opset to PCT (minutes) 288 (196 3-389 8) 300 (220-413 2) 230 (148 5-341 5) 0.094 | Undetermined | 2 (4.3%) | 2 (6.5%) | 0 (0%) | |
| | Time from symptoms onset to PCT (minutes) | 288 (196.3–389.8) | 300 (220–413.2) | 230 (148.5–341.5) | 0.094 |
| Aura symptoms during CT 23 (48.9%) 13 (41.9%) 10 (62.5%) 0.304 | Aura symptoms during CT | 23 (48.9%) | 13 (41.9%) | 10 (62.5%) | 0.304 |
| Time from end of symptoms to CT [92 (110–333.3) 280 (120–346.7) 171 (89.2–330.8) 0.697 | Time from end of symptoms to CT | 92 (0-333.3) | 280 (120–346.7) | 7 (89.2–330.8) | 0.697 |
| IV thrombolysis $ (2,1\%) $ $ (3,2\%) $ $0(0\%) $ $1,000 $ | IV thrombolysis | (2.1%) | (3.2%) | 0 (0%) | 1.000 |
| Follow-up MRI performed 35 (74,5%) 21 (67.7%) 14 (87.5%) 0.263 | Follow-up MRI performed | 35 (74.5%) | 21 (67.7%) | 14 (87.5%) | 0.263 |
| Time from onset to MRI (days) 3 (1–9.6) 4.5 (1–13.2) 2.8 (1-6) 0.341 | Time from onset to MRI (days) | 3 (1–9.6) | 4.5 (1–13.2) | 2.8 (1-6) | 0.341 |

Table I. Clinical features of patients with migraine with aura (MA) with and without focal hypoperfusion (FHP) on perfusion-CT (PCT).

In bold significant values with p < 0.05.

or a whole hemisphere (56% vs 7%) (p < 0.001). The qualitative analysis of PCT capable of distinguishing focal or single-territory hypoperfusion versus adjacent-territory or hemispheric hypoperfusion showed an AUC of 0.92 (95% CI 0.85–0.99), with 90% sensitivity and 94% specificity. On investigation of single PCT parameters, MA patients had a less pronounced increase in rMTT (1.2 vs 1.8, p < 0.001) and rTTP (1.1 vs 1.2, p < 0.001), and a lesser decrease in rCBF (0.8 vs 0.6, p < 0.001) compared with TIA patients. rCBV was slightly reduced in MA and slightly

| Variables | Patients with transient neurological deficit(s) (n=90) | MA patients with FHP (n = 16) | TIA patients with FHP (n = 74) | p-Value |
|---------------------------------------|--|-------------------------------|--------------------------------|---------|
| Age (years) | 64 (48–77) | 33 (21.7–58.5) | 69.5 (57–78) | <0.001 |
| Female sex | 40 (44.4%) | 8 (50%) | 32 (43.2%) | 0.829 |
| Vascular risk factors | | | | |
| Arterial hypertension | 53 (58.9%) | 3 (18.8%) | 50 (67.6%) | 0.001 |
| Diabetes | 12 (13.3%) | I (6.2%) | 11 (14.9%) | 0.607 |
| Dyslipidemia | 58 (64.4%) | 2 (12.5%) | 56 (75.7%) | <0.00 l |
| Smoking | 37 (41.1%) | l (6.2%) | 36 (48.6%) | 0.004 |
| Atrial fibrillation | 22 (24.4%) | 0 (0%) | 22 (29.7%) | 0.029 |
| Neurological symptoms | | | | |
| Duration of neurological deficit | 145 (49.6–420) | 205 (120-695) | 120 (30–360) | 0.049 |
| Paresis | 55 (61.1%) | 6 (37.5%) | 49 (66.2%) | 0.064 |
| Dysarthria | 31 (34.4%) | l (6.2%) | 30 (40.5%) | 0.020 |
| Sensory symptoms | 36 (40%) | 11 (68.8%) | 25 (33.8%) | 0.021 |
| Limb ataxia | 9 (10%) | 3 (18.8%) | 6 (8.1%) | 0.408 |
| Visual symptoms | 21 (23.3%) | 9 (56.2%) | 12 (16.2%) | 0.002 |
| Aphasia | 61 (67.8%) | 13 (81.2%) | 48 (64.9%) | 0.329 |
| Neglect | 6 (6.7%) | 0 (0%) | 6 (8.1%) | 0.531 |
| Other cognitive deficit | 15 (16.7%) | 5 (31.2%) | 10 (13.5%) | 0.175 |
| Side of neurological symptoms | | | | 0.226 |
| Right | 24 (26.7%) | 4 (25%) | 20 (27%) | |
| Left | 62 (68.9%) | 10 (62.5%) | 52 (70.3%) | |
| Bilateral | 4 (4.4%) | 2 (12.5%) | 2 (2.7%) | |
| Time from symptoms onset to PCT (min) | 220 (137.7–331.9) | 230 (148.5–341.5) | 220 (133.8–331.9) | 0.673 |
| Symptoms during CT | 44 (48.9%) | 10 (62.5%) | 34 (46%) | 0.355 |
| PCT results | | | | |
| Topography of hypoperfusion | | | | <0.00 l |
| Focal | 53 (58.9%) | 0 (0%) | 53 (71.6%) | |
| Single vascular territory | 15 (16.7%) | l (6.2%) | 14 (18.9%) | |
| Adjacent vascular territories | 8 (8.9%) | 6 (37.5%) | 2 (2.7%) | |
| Hemispheric | 14 (15.6%) | 9 (56.2%) | 5 (6.8%) | |
| MTT (s) | 9.2 (2.6) | 7 (1.9) | 9.7 (2.5) | <0.00 l |
| TTP (s) | 22.6 (4.6) | 18.6 (3.2) | 23.4 (4.5) | <0.00 l |
| CBV (mL/100g) | 3.5 (0.8) | 3.3 (0.5) | 3.5 (0.8) | 0.098 |
| CBF (mL/100g/min) | 30.7 (12.6) | 38.5 (14.3) | 29 (11.7) | 0.021 |
| MTT ratio | 1.7 (0.5) | 1.2 (0.1) | 1.8 (0.5) | <0.00 l |
| TTP ratio | 1.2 (0.1) | 1.1 (0) | 1.2 (0.1) | <0.00 l |
| CBV ratio | 1.1 (0.2) | 0.9 (0.1) | 1.1 (0.2) | <0.00 l |
| CBF ratio | 0.6 (0.2) | 0.8 (0.1) | 0.6 (0.2) | <0.00 l |
| Follow-up MRI | | | | |
| MRI performed | 42 (46.7%) | 14 (87.5%) | 28 (37.8%) | 0.001 |
| Time from onset to MRI (days) | 5 (2–6.1) | 2.8 (1-6) | 5 (4-7) | 0.074 |

Table 2. Clinical and radiological features of patients with migraine with aura (MA) and focal hypoperfusion (FHP) on perfusion CT and of patients with transient ischemic attack (TIA) and FHP.

In bold significant values with p < 0.05.

augmented in TIA (0.9 vs 1.1 respectively, p < 0.001) (Table 2).

From ROC curve analyses of PCT parameters, we found that rMTT displayed the best discriminative ability for differentiating MA from TIA (AUC 0.88, 95% CI 0.81–0.95) (Figure 2). We identified an optimal rMTT cut-off of <1.32, which had a sensitivity of 93% and a qu

specificity of 82% for distinguishing FHP in MA from that of TIA.

Combining both qualitative and quantitative PCT data led to an AUC=0.97, 95% CI 0.93–0.99), not significantly different from the AUC of the quantitative or qualitative data alone (De-Long tests, p > 0.05). After the addition of quantitative data, two patients were correctly reclassified as

Figure 2. Receiver operating characteristic (ROC) curves for different PCT parameters to differentiate migraine aura from TIA.

TIA from migraine and one patient incorrectly reclassified as migraine from TIA.

Discussion

In our retrospective study of MA patients with acute-onset hemispheric/lateralized neurological deficits who underwent PCT, we found focal hypoperfusion in one-third of patients. Compared with PCT findings in patients with TIA, focal hypoperfusion in MA involved adjacent arterial territories more frequently and was less severe. The analysis of single PCT parameters showed that the smaller increase in rMTT best differentiated MA from TIA.

The occurrence of cerebral hypoperfusion during MA is a known phenomenon, already described in SPECT and MRI studies.¹⁰ On the other hand, the ability of PCT to detect such perfusion abnormality has mainly been described in single-case reports,11,12 and only in one case series.⁸ In the latter, a quantitative assessment of PCT maps was adopted, showing perfusion abnormalities in 13/14 patients with MA, with the most frequently altered parameter being MTT. The observed perfusion changes were above the CBV threshold for ischemic core and below the MTT threshold for penumbra. This is in line with our finding of less marked perfusion changes in MA than in TIA patients. Of note, the time from aura symptoms onset and resolution and the presence of these symptoms at the time of imaging execution might affect the chance of detecting perfusion abnormality. Accordingly, in patients with FHP we observed a shorter delay from aura symptoms onset and resolutions to imaging and a higher frequency of symptom at the time of imaging. However, these differences were not statistically significant, possibly for the limited sample size, not allowing us to draw definite conclusion on the relationship between aura temporal evolution and prevalence of FHP.

Our results are also consistent with previous MRI-based studies showing that hypoperfusion in almost all cases of MA involved adjacent vascular territories,^{13,14} and was associated with lower TTP and MTT ratios compared to patients with AIS.¹⁴ In addition, we demonstrated that the CBV ratio was significantly lower and the CBF ratio significantly higher in comparison to patients with TIA. These findings suggest that in migraine with aura, hypoperfusion is generally less severe and does not fall below a critical limit defining ischemic lesion.

Our research group already studied hypoperfusion characteristics in patients with TIA who underwent PCT,¹⁵ and we previously demonstrated that they might be useful in differential diagnosis from other conditions, including transient global amnesia or posterior reversible encephalopathy syndrome.^{16,17} Similarly, in the present study, we suggest that a CTP-quantitative analysis might detect a moderate hypoperfusion pattern in the cerebral regions during MA, compatible with aura symptoms, which could help in distinguishing from TIA.

The clinical implications of our study are related to the potential role of PCT in the management of patients presenting with acute-onset focal neurological deficits. The differential diagnosis between MA and AIS can be clinically challenging, even more so with TIA given that TIA may be characterized by transient symptoms and absence of ischemic lesion on neuroimaging. Furthermore, focal hypoperfusion on PCT or PWI in MA patients could also be treated as ischemia, in particular if the above-described MA-specific features are not considered. This challenging diagnosis in the emergency setting is further complicated by the fact that migraine patients may themselves experience a cerebrovascular accident, which could be misinterpreted as an MA attack (i.e. stroke chameleons).

Even if the hemorrhagic risk for rtPA administered to patients with stroke mimic is low, and there is no report of post-rtPA intracerebral hemorrhage in patients with MA, the misdiagnosis of MA as a neurovascular event remains a non-negligeable matter.² Awareness of PCT characteristics can help to distinguish properly migraine with aura from cerebrovascular diseases and to avoid unnecessary procedures and treatments in patients showing perfusion deficit involving adjacent vascular territories and with only a moderate increase in MTT. On the contrary, hypoperfusion restricted to a single vascular territory in combination with a marked increase in MTT should be regarded as atypical for migraine aura and suggestive rather of TIA. This information may lead to a correct diagnosis based on clinical evaluation and CTP data, without the need of additional imaging such as brain-MRI.



Limitations of our study include the retrospective design and its moderate sample size; however, to our knowledge, this is the largest series of patients investigating perfusion abnormalities in MA compared with transient ischemic attack. Still, the limited number of included patients did not allow us to perform adjusted statistical analyses. Some patients in the MA group did not fulfill all ICHD criteria of migraine with aura as they had no previous attacks of MA. In these cases, the diagnosis was based on the evaluation by a board-certified neurologist who considered MA the most likely pathophysiological process to explain the event. Also, as perfusion imaging was carried out as part of clinical practice, no additional perfusion imaging was obtained that would have allowed studying the natural course of FHP. Of note, the decrease of brain transit time with aging should be considered as a potential confounder when comparing perfusion parameters between two population with large age difference such as MA and TIA (36 vs 64 years respectively in our study). We likely minimized this effect since we used the ratio of PCT parameters between the visibly hypoperfused region and the contralateral side.

In conclusion, in our collection of patients with migraine with aura assessed by PCT, we were able to identify a characteristic perfusion pattern with areas of hypoperfusion often affecting adjacent vascular territories and showing a lower increase in MTT ratio compared to transient ischemic attack. Knowledge of specific PCT findings in migraine with aura could be useful in the acute management and correct identification of these patients. Further prospective studies examining the role of emergency PCT in reducing the misdiagnosis of stroke mimics, including migraine with aura, are strongly welcomed.

Acknowledgements

We thank Melanie Price Hirt for English language correction and editing.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D. Strambo: Research grants from the Swiss Heart Foundation and the University of Lausanne (not related to this work). V. Dunet: Research grant from the Swiss National Science Foundation (not related to this work). P. Michel: Research grants from the Swiss National Science Foundation and Swiss Heart Foundation; consulting fees from Medtronic (all used for research and education). The other authors declare no conflict of interest.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Swiss Heart Foundation.

Ethical approval and informed consent

No informed consent nor local ethical committee approval was required for retrospective analysis of anonymized data according to the legislation of the Canton de Vaud, Switzerland.

Guarantor

DS

Contributorship

DS: clinical data acquisition, statistical analysis and interpretation and draft of the manuscript. SN: study conception and design, clinical data acquisition, and draft of the manuscript. LR: clinical data acquisition, critical revision of the manuscript. VD: radiological data acquisition, critical revision of the manuscript. PM: study conception and design, data acquisition, statistical analysis and interpretation and draft of the manuscript.

ORCID iDs

Davide Strambo Davide Strambo https://orcid.org/0000-0003-4429-2714 Stefania Nannoni https://orcid.org/0000-0002-1825-1874

References

- 1. Vilela P. Acute stroke differential diagnosis: stroke mimics. *Eur J Radiol* 2017; 96: 133–144.
- Terrin A, Toldo G, Ermani M, et al. When migraine mimics stroke: a systematic review. *Cephalalgia* 2018; 38: 2068–2078.
- 3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia* 2018; 38: 1–211.
- Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. *Cephalalgia* 2010; 30: 780–792.
- Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. *Lancet* 2019; 394: 139–147.
- Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med* 2018; 378: 708–718.
- Ridolfi M, Granato A, Polverino P, et al. Migrainous aura as stroke-mimic: the role of perfusion-computed tomography. *Clin Neurol Neurosurg* 2018; 166: 131–135.
- Granato A, D'Acunto L, Ajčević M, et al. A novel computed tomography perfusion-based quantitative tool for evaluation of perfusional abnormalities in migrainous aura stroke mimic. *Neurol Sci* 2020; 41: 3321–3328.
- Abul-Kasim K, Strömbeck A, Maly P, et al. Interobserver and intraobserver agreement in the evaluation of CT perfusion in ischemic stroke. *Funct Neurol* 2009; 24: 139–145.
- Hansen JM and Schankin CJ. Cerebral hemodynamics in the different phases of migraine and cluster headache. J Cereb Blood Flow Metab 2019; 39: 595–609.
- Shah L, Rana S, Valeriano J, et al. Reversible CT perfusion abnormalities in patient with migraine variant: a two phase process. *Clin Neurol Neurosurg* 2013; 115: 830–832.
- Roth C, Ferbert A, Huegens-Penzel M, et al. Multimodal imaging findings during severe attacks of familial hemiplegic migraine type 2. *J Neurol Sci* 2018; 392: 22–27.
- Floery D, Vosko MR, Fellner FA, et al. Acute-onset migrainous aura mimicking acute stroke: MR perfusion imaging features. *AJNR Am J Neuroradiol* 2012; 33: 1546–1552.
- Förster A, Wenz H, Kerl HU, et al. Perfusion patterns in migraine with aura. *Cephalalgia* 2014; 34: 870–876.

- 15. Meyer IA, Cereda CW, Correia PN, et al. Factors associated with focal computed tomographic perfusion abnormalities in supratentorial transient ischemic attacks. *Stroke* 2018; 49: 68–75.
- 16. Vanacker P, Matias G, Hagmann P, et al. Cerebral hypoperfusion in posterior reversible encephalopathy syndrome is

different from transient ischemic attack on CT perfusion. J Neuroimaging 2015; 25: 643–646.

 Meyer IA, Wintermark M, Démonet JF, et al. CTP in transient global amnesia: a single-center experience of 30 patients. *AJNR Am J Neuroradiol* 2015; 36: 1830–1833.